New palonosetron-aprepitant trial data on chemotherapy induced nausea, vomiting presented at EHA

New data presented at the European Hematology Association (EHA) 2011 Annual Meeting in London show better control of nausea and vomiting with the combination palonosetron plus aprepitant when compared to granisetron in patients receiving multiday highly emetogenic conditioning chemotherapy regimens - Significantly higher the complete response during the acute, delayed and overall periods

The combination of palonosetron (0.25 mg iv every 48 h) and aprepitant (125 mg on day 1, followed by 80 mg each of the remaining days) improves control of CINV (Chemotherapy Induced Nausea and Vomiting) compared with daily granisetron (3 mg iv) during the conditioning period (5-6 days) of patients prior to stem cell transplantation (HSCT).

The results come from a prospective, multicenter, randomized, stratified by conditioning regimen, double-blind study (AMENO Study) presented at the European Hematology Association (EHA) 2011 Annual Meeting in London by the Spanish groups GETH (Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular) and PETHEMA (Programa de Estudio y Tratamiento de las Hemopatias Malignas).

"Nausea and vomiting in patients receiving high-dose, multiday conditioning regimens prior to stem cell transplantation is particularly common and affects between 55 and 100% of the patients," Javier Lopez-Jimenez, Hospital Ramon y Cajal, Hematology Department and the lead investigator, said. "CINV is particularly troublesome, especially in the delayed phase beginning 24 hours after the start of conditioning. Though newer anti-emetics as palonosetron and aprepitant appear to significantly reduce acute and delayed CINV, in comparison to the older 5-HT3 receptor antagonists, few studies had prospectively evaluated the efficacy of these drugs in this very challenging setting," he explained.

Source:

GETH and PETHEMA

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
High-dose chemotherapy followed by immunotherapy benefits patients with acute myeloid leukemia